546 related articles for article (PubMed ID: 19017914)
1. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
2. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
Hapani S; Sher A; Chu D; Wu S
Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
6. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis.
Chen XL; Lei YH; Liu CF; Yang QF; Zuo PY; Liu CY; Chen CZ; Liu YW
PLoS One; 2013; 8(6):e66721. PubMed ID: 23818962
[TBL] [Abstract][Full Text] [Related]
8. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
Hapani S; Chu D; Wu S
Lancet Oncol; 2009 Jun; 10(6):559-68. PubMed ID: 19482548
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
10. Risk of serious neutropenic events in cancer patients treated with bevacizumab: a meta-analysis.
Zhou F; Shao JH; Wu LQ; Yin XB; Yu X
Asian Pac J Cancer Prev; 2013; 14(4):2453-9. PubMed ID: 23725157
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
Schutz FAB; Je Y; Azzi GR; Nguyen PL; Choueiri TK
Ann Oncol; 2011 Jun; 22(6):1404-1412. PubMed ID: 21115602
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis.
An MM; Zou Z; Shen H; Liu P; Chen ML; Cao YB; Jiang YY
Eur J Clin Pharmacol; 2010 Aug; 66(8):813-21. PubMed ID: 20401474
[TBL] [Abstract][Full Text] [Related]
15. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Zhu X; Wu S; Dahut WL; Parikh CR
Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
[TBL] [Abstract][Full Text] [Related]
16. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
Zhan P; Wang Q; Qian Q; Yu LK
Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups.
Qi WX; Fu S; Zhang Q; Guo XM
Clin Drug Investig; 2014 Oct; 34(10):681-90. PubMed ID: 25096848
[TBL] [Abstract][Full Text] [Related]
18. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
Schutz FA; Jardim DL; Je Y; Choueiri TK
Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
[TBL] [Abstract][Full Text] [Related]
19. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
[TBL] [Abstract][Full Text] [Related]
20. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
Seng S; Liu Z; Chiu SK; Proverbs-Singh T; Sonpavde G; Choueiri TK; Tsao CK; Yu M; Hahn NM; Oh WK; Galsky MD
J Clin Oncol; 2012 Dec; 30(35):4416-26. PubMed ID: 23150697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
